Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Dual Effects of Atorvastatin on Angiogenesis Pathways in the Differentiation of Mesenchymal Stem Cells Publisher Pubmed



Khalighfard S1, 2 ; Khori V3 ; Alizadeh AM2 ; Vahabzadeh G4 ; Tajaldini M3 ; Sedighi S3 ; Nozarian Z5 ; Khodayari H6 ; Khodayari S6 ; Ganji F7 ; Veisi Malekshahi Z8 ; Mirmajidi T2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
  4. 4. Department of Pharmacology, School of Medicine, Iran University of Medical Science, Tehran, Iran
  5. 5. Department of Pathology, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. International Center for Personalized Medicine, Dusseldorf, Germany
  7. 7. Department of Tissue Engineering & Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
  8. 8. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: European Journal of Pharmacology Published:2021


Abstract

Atorvastatin (ATO) can improve the transplantation efficacy of mesenchymal stem cells (MSCs) after acute myocardial infarction. The present study aimed at ATO effects on the angiogenesis-signaling pathways from MSCs' differentiation to tissue angiogenesis. MSCs were first prepared from BALB/c mouse bone marrow. MTT assay was then done for the biodegradability of MSCs with the extracellular matrix. After that, the differentiation of cells into the bone and fat tissues was confirmed by Alizarin and Oil Red O staining. The extracellular matrix was then combined with the cells to the implant. Animals were intraperitoneally treated with ATO (2 and 40 mg/kg, daily) three days before cell transplantation to one week after. Finally, the assays were carried out by electron microscopy, immunocytochemistry, ELISA, Western blot, and RT-qPCR techniques. A phase-contrast microscope confirmed the morphology of cells. The cell differentiation into bone and fat tissues was confirmed by Alizarin red staining and flow cytometry, and the cell proliferation was confirmed by MTT assay. Unlike ATO 40 mg/kg group, ATO 2 mg/kg was significantly increased the CD31, eNOS, podocalyxin, von Willibrand factor, and alpha-smooth muscle actin proteins levels compared to the control group in vitro experiment. The expression of CD31 and VEGF proteins, as angiogenesis markers, and Ki-67 protein, as a proliferation marker, was significantly higher in a low dose of ATO (2 mg/kg) than that of the control group in vivo experiment. Unlike ATO 40 mg/kg, the expression levels of ERK, AKT, NF-ҝB, Rho, STAT3, Ets-1, HIF-1α, and VEGF proteins and genes were significantly increased in ATO 2 mg/kg compared to the control. A low dose of ATO can be a beneficial tool in the function of MSCs and their differentiation to tissue angiogenesis. © 2021 Elsevier B.V.